Welcome to Drug and Alcohol Treatment
| ||
Drug Treatment Rcc Article
This is a selection made from among articles on Drug Treatment Rcc. For a permanent link to this article, or to bookmark it for future reading, click here.
from:
The Importance of Alcohol Rehab Centers
By Paul S. Allen
Alcohol dependency affects over 15 million Americans, with a shocking half a million of those between the ages of 9 and 12. Alcohol and alcohol related problems contribute to at least $100 million in annual health care costs and loss of productivity. Nearly a quarter of those admitted to hospitals have some type of alcohol problem or are diagnosed for alcohol related consequences. With the statistics at crisis levels, it's important to examine the role that alcohol rehab centers can play in solving these problems.
There are three main approaches to alcohol rehabilitation: Behavioral therapies, 12-step programs, and pharmacological treatment. Most inpatient rehab centers employ a combination of approaches to provide more comprehensive treatment.
Alcoholics Anonymous is the most well-known 12-step program. Most treatment programs, whether outpatient or inpatient, encourage patients to attend one of these self help groups. Some even offer 12-step meetings within their facilities or educate the patient about the program in a learning environment. Behavioral therapies are designed to prevent relapse by teaching the skills necessary to avoid temptation and function normally once their initial treatment is complete. Pharmacological treatment includes the use of medications such as disulfiram and naltrexone to combat the physical symptoms and urges of alcohol dependency.
In 1999, more than 700,000 people received treatment for alcohol each day. A vast majority of them were treated in outpatient facilities. The more intense type of this treatment involves the patient visiting a hospital treatment program for several hours a day on several days a week. The less intensive form of outpatient treatment focuses on counseling sessions once or twice a week, sometimes involving group sessions and family therapy as well as individual counseling.
The advantages of outpatient treatment include lower treatment costs, shorter treatment programs, and the ability to maintain outside relationships and activities while undergoing treatment.
Inpatient alcohol rehab traditionally lasts for 28 days. However, with rising health care costs, this number is diminishing. Studies in the mid 1990s found that inpatient treatment is especially helpful for patients with additional medical and/or psychiatric conditions (also known as dual-diagnosis patients) or for those whose environments are not supportive of rehabilitation.
In addition to the 28 day rehabilitation program, some alcohol rehab centers offer extended stay treatments. These programs allow a patient to enter a therapeutic community for six to twelve months, providing the time necessary for both detoxification and counseling as well as social and occupational therapies that can help them function better once they return to society. These programs are ideal for patients with longer histories of addiction, impaired social functioning, or involvement in serious criminal activities. Alcohol rehab programs that treat adolescents and children also provide for continuing education, such as high school and college courses during the inpatient stay. The longer treatment plan allows for the slow re-socialization of patients to a drug-free and crime-free life.
One of the cornerstones of successful alcohol rehab is detoxification. The symptoms associated with cessation of alcohol consumption are collectively referred to as alcohol withdrawal syndrome. These can include insomnia, irritability, tremors, seizures, delirium tremens, and hallucinations. As a result of the dangers of these sometimes life-threatening symptoms, many alcohol rehab programs require an initial period of detoxification. Even if an alcoholic will be getting outpatient treatment, they may require inpatient detox first. However, there are some detox programs that are administers on an outpatient basis, when the alcohol withdrawal syndrome is less severe.
A successful alcohol rehab center will have a trained, professional staff that ensures quality individual support of patients while maintaining an alcohol and drug-free environment. It will provide comprehensive counseling, education, and referrals to community resources for continuing recovery after treatment. It will offer alcohol and drug education to its patients while conducting outreach to reduce the stigma of addiction and alcoholism in its surrounding community. Most importantly, a quality alcohol rehab center will have a documented record of success rate in rehabilitating patients and the ability to demonstrate the longevity of their patient recovery.
The ultimate goal of alcohol rehabilitation is a productive and sober life for the alcoholic once they complete treatment. The ability of a rehab program to provide the addict with treatment and usable skills to help them abstain from alcohol (or to consume in controlled moderation) is their true measure of success.
Gatehouse Academy is a long term, residential drug and alcohol rehab center exclusively for young adults age 17 - 25. Residents learn life skills, attend therapy, continue formalized education, enhance physical well-being, and recover from the effects of alcohol & drug abuse through focused 12 Step Recovery. For more information on Gatehouse Academy call toll free @ (888) 966-4800
Article Source: http://EzineArticles.com/?expert=Paul_S._Allen
http://EzineArticles.com/?The-Importance-of-Alcohol-Rehab-Centers&id=946262
Drug Treatment Rcc Specific links
Drug Treatment Rcc News
Pfizer says EU recommends approval of Inlyta - CBS News
Pfizer says EU recommends approval of Inlyta CBS News NEW YORK — Pfizer Inc. said Friday that European Union regulators are recommending approval for its kidney cancer drug Inlyta. A European Union advisory committee recommended that Inlyta be approved as a treatment for advanced renal cell carcinoma in ... |
Inlyta Promising as First-Line RCC Treatment - MedPage Today
Inlyta Promising as First-Line RCC Treatment MedPage Today CHICAGO -- The angiogenesis blocking drug axitinib (Inlyta), currently approved as a second-line treatment in advanced kidney cancer, might also be useful in treatment-naive patients, researchers said. In a phase II study, previously untreated patients ... |
Targeted Therapies Drive the Global Renal Cell Carcinoma (RCC) Drugs Market ... - San Francisco Chronicle (press release)
Targeted Therapies Drive the Global Renal Cell Carcinoma (RCC) Drugs Market ... San Francisco Chronicle (press release) The global market for Renal Cell Carcinoma (RCC) Drugs is forecast to reach $3.03 billion by the year 2017, driven by the growing preference for targeted therapies in the treatment of RCC. Additionally, growth is also expected to stem from the ... |
Pfizer Provides Topline Results From Phase 3 Study Of Torisel(R) As Second ... - MarketWatch (press release)
Pfizer Provides Topline Results From Phase 3 Study Of Torisel(R) As Second ... MarketWatch (press release) (1) Between 40 and 65 percent of patients in the US who progress following first-line therapy go on to receive a second-line treatment.(2,3,4) "This trial advances our knowledge about TORISEL in RCC. TORISEL remains an important drug for treatment of ... Pfizer Phase III renal cell carcinoma study fails to meet primary endpoint Pfizer Reports Results From Phase 3 Study Of Torisel - Quick Facts Results from phase-3 trial of Pfizer cancer drug disappoint |
Crossing the country to beat cancer - BlueRidgeNow.com
Crossing the country to beat cancer BlueRidgeNow.com Without even needing a biopsy to confirm his findings, the urologist's diagnosis was swift and certain: Wise had a growth in his left kidney, and it was stage 4 clear cell renal cell carcinoma, an incurable type of kidney cancer. Without treatment ... |
AVEO and Astellas Announce Positive Findings from TIVO-1 Superiority Study of ... - MarketWatch (press release)
AVEO and Astellas Announce Positive Findings from TIVO-1 Superiority Study of ... MarketWatch (press release) "TIVO-1 is novel in that this Phase 3 clinical study used an approved targeted comparator drug to evaluate first-line RCC treatment," said Dr. Motzer. "Patients in the study who had no prior treatment for advanced kidney cancer and who were given ... |
Novel Anti-VEGF Drug Effective in Kidney Cancer - MedPage Today
Novel Anti-VEGF Drug Effective in Kidney Cancer MedPage Today ... three VEGF receptors demonstrated significant improvement in progression-free survival and objective response rate compared with sorafenib as initial targeted treatment for advanced renal cell carcinoma. CHICAGO -- An investigational drug targeting ... New Drug Shows Promise for Patients with Advanced Kidney Cancer |
Astellas & AVEO: Tivozanib Successfully Demonstrates the Longest Reported ... - MarketWatch (press release)
 Xconomy | Astellas & AVEO: Tivozanib Successfully Demonstrates the Longest Reported ... MarketWatch (press release) HR = 0.756, p=0.037(1) TIVO-1 is a global, randomised Phase III superiority clinical trial evaluating the efficacy and safety of investigational drug tivozanib compared to the approved treatment sorafenib, in 517 patients with advanced RCC. AVEO and Astellas Announce Positive Findings from TIVO-1 Superiority Study of ... Aveo kidney cancer drug more tolerated than Nexavar Aveo Kidney Cancer Drug Shows Safety Edge in Pivotal Study |
Disappointing Data on Pfizer Drug - Zacks.com
Disappointing Data on Pfizer Drug Zacks.com The company is looking to expand Torisel's label for use in advanced renal cell carcinoma (RCC) patients whose disease has progressed while on or after being treated with Sutent. Results from the phase III INTORSECT (B1771003) study showed that Torisel ... Torisel fails in head-to-head study with Nexavar Torisel fails to top Bayer's Nexavar as second-line kidney cancer treatment Pfizer's Torisel loses out to Bayer's Nexavar in PFS trial |
Aveo, Astellas Report Positive Data from Phase III Comparative Tivozanib Trial ... - Genetic Engineering News
Aveo, Astellas Report Positive Data from Phase III Comparative Tivozanib Trial ... Genetic Engineering News Tivo-1 enrolled patients with advanced clear cell RCC, who had undergone prior nephrectomy and had not previously been treated using a targeted therapy. The trial data showed that tivozanib therapy resulted in a median progression free survival of 12.7 ... |